论文部分内容阅读
目的:评价阿托伐他汀钙对2型糖尿病伴高脂血症患者的降脂疗效。方法:选取2012年12月—2014年3月间医院收治的2型糖尿病伴高脂血症患者90例,将其分为对照组和观察组(每组45例);对照组患者予口服辛伐他汀片治疗,观察组患者予口服阿托伐他汀钙胶囊治疗,疗程均为8周,比较两组患者血脂指标、显效率、有效率及不良反应的发生情况。结果:治疗后两组患者血脂指标(TC、TG、HDL-C、LDL-C、APo A、APo B)均明显优于治疗前(P<0.05),观察组患者的血脂指标(除APo A外)、显效率、有效率均优于对照组患者(P<0.05);两组患者不良反应的发生率经比较其差异无统计学意义(P>0.05)。结论:阿托伐他汀钙用于治疗2型糖尿病伴高脂血症患者的降脂疗效优于辛伐他汀。
AIM: To evaluate the lipid-lowering efficacy of atorvastatin calcium in type 2 diabetic patients with hyperlipidemia. Methods: Ninety patients with type 2 diabetes mellitus and hyperlipidemia admitted from December 2012 to March 2014 in our hospital were divided into control group and observation group (45 cases in each group). Patients in the control group were given oral Xin The patients in the observation group were given oral atorvastatin calcium capsules for 8 weeks. The levels of blood lipid, effective rate, effective rate and adverse reactions in the two groups were compared. Results: The levels of serum lipids (TC, TG, HDL-C, LDL-C, APoA and APo B) in the two groups were significantly better than those before treatment (P <0.05) (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Atorvastatin calcium is superior to simvastatin in the treatment of type 2 diabetes with hyperlipidemia.